EXACT Sciences Corporation (EXAS) Quote

Well, yesterday's selling was a bit of a wallop! An open GTC Limit Order snagged a few shares to build inventory.
https://finance.yahoo.com/news/exact-sciences-third-quarter-2024-102053595.html
Seems like an excessive sell-off for the "miss" on revenues and earnings.
Still, I'd like to see a string of profitable quarters, myself.
Best wishes,
OAG

FDA approves EXAS’ Cologuard Plus*—a follow-on to Cologuard to be launched in 2025:

https://www.businesswire.com/news/home/20241004761985/en

Compared to original Cologuard, Cologuard Plus has new biomarkers for (modestly) improved sensitivity/specificity and enhanced stabilizers to allow patients more time to return their samples to EXAS’ lab for analysis. One glitch with original Cologuard has been a relatively high rate of invalid test results due to the patients’ not returning their samples quickly enough.

*f/k/a Cologuard 2.0.

EXAS $75; most recent high

Well, that was a nice uptick in share price today.
https://schrts.co/sFVDWhrv

It should move up 25% every day!

Best wishes,
OAG

EXAS claims Cologuard 2.0 superiority_to_existing Cologuard, but Evaluate Vantage says lack of improved sensitivity for pre-cancerous lesions is disappointing:

https://finance.yahoo.com/news/next-generation-cologuard-test-demonstrates-200500387.html

https://www.evaluate.com/vantage/articles/news/trial-results/exacts-next-gen-cancer-screen-beats-original

The new version of Cologuard won’t be commercially available until 2024.

EXAS up big time in the pre-market. I've added to my EXAS position several times as the price has been out of favor. A bump upward will make me happy.

Best wishes,
OAG Tom

GH—(-34%/AH)—reports_results_of “Shield” ctDNA—(liquid biopsy)—diagnostic_for colorectal cancer:

https://finance.yahoo.com/news/guardant-health-announces-positive-results-211600504.html

https://finance.yahoo.com/news/1-guardant-dna-blood-test-220041937.html

GH’s data aren’t bad, but they aren’t as good as those for EXAS’s Cologuard, which is based on a stool sample rather than a blood sample.

EXAS is +24%/AH, adding about $2B(!) to its market cap.

In #msg-168735158 (from May 2022), I said: Although GH says Shield is as good as EXAS’ Cologuard and MYNZ’s ColoAlert, I find it hard to believe that a blood test can be as sensitive for CRC (and precancerous lesions) as a stool-based test.I stand by that.

Exact Sciences to buy Prevention Genetics and expand cancer screening capabilities.................

https://www.wisbusiness.com/2022/tue-am-news-exact-sciences-expanding-cancer-diagnostics-capabilities-with-190m-acquisition-covid-cases-continue-to-escalate-amid-omicron-surge/

Best wishes,
OAG Tom

Results in multi~Billion~$$ opportunity for EXAS if they execute on PCHM Teleheatlth phlebotomy replacement
Choice~Wording PATCHING "Exact~Sciences: Patching The Acquisitions Together" h ttps://seekingalpha.com/article/4400134-exact-sciences-patching-acquisitions-together EXAS PCHM

Exact Sciences is pursuing it by acquiring complementary companies.


PharmChek® Specimen Container For Collection; a Class I & II Device: Cleared by the FDA on October 4, 1990, this vessel has been proven as a non-invasive tool to collect excreted sweat for testing in clinical trials and research studies. https://investorshub.advfn.com/boards/read_msg.aspx?message_id=161329158

You're patching it all together. PCHM an acquisition target.

Yes EXAS, GH and QTRX all great companies in healthcare/medical field and all three doing tremendous, and appear they will keep rising IMO

It's amazing how quickly this stock has doubled.

OAG

go exas

That's a nice upward move for EXAS.

OAG Tom

EXAS > Exact Sciences shares are trading higher after the company issued Q4 sales guidance above analyst estimates.

A Sweat-based Wearable Enabling Technology for Real-time Monitoring of IL-1ß and CRP as Potential Markers for Inflammatory Bowel Disease
Jagannath B, Lin KC, Pali M, Sankhala D, Muthukumar S, Prasad S.
Inflamm Bowel Dis. 2020 Sep 18;26(10):1533-1542. doi: 10.1093/ibd/izaa191.
PMID: 32720974
Sweat was collected using an FDA-approved PharmChek patch from 26 healthy human subjects to determine the levels of the 2 study inflammatory markers

https://pubmed.ncbi.nlm.nih.gov/32720974/

Sweat was collected using an FDA-approved PharmChek patch

whats EXAS gonna do with all this new cash raise???? PCHM
Poop in a box sweat on a patch home diagnosis market is gargantuan

ARK bought in today a huge amount of shares..better sell to profit b4 they sell theirs

Won’t the purchase and sale of >8M shares dilute the value plus the sale price at $101...

Earnings miss? Why am I seeing mixed earnings reports? As far as I can tell they missed with $1.46 loss per share based on the report on their own website while other financial sites like zachs on nasdaq.com was showing a 29% earnings beat. Surprised this earnings miss didn’t outweigh the news of the merger, I would expect it to continue losses as these new companies will not be adding to profitability for a while...

* * $EXAS Video Chart 10-27-2020 * *

Link to Video - click here to watch the technical chart video

is it PCHM EXAS JV talk that's lifting it higher?
poop in a box sweat on a patch home diagnosis market is huge!
what a pair they would make

Great SHORT here ..brutally overpriced at $19 billion for a company which is unprofitable

Nice chart! I like to see some $200.00+ price targets.

EXAS

Still going, good looking company imo!

123.50 > new 52 week high > up 15%

Exact Sciences shares are trading higher after the company reported better-than-expected Q3 sales results. The company also announced it will acquire Thrive for $2.15 billion in cash and stock.

Exact Sciences Reportedly Unveils Liquid Biopsy With Multiple Cancer Detection

9/24/20, 2:50 PM
02:50 PM EDT, 09/24/2020 (MT Newswires) -- Exact Sciences (EXAS) CEO Kevin Conroy reportedly unveiled data at a summit from a liquid biopsy that detected multiple cancers from a blood sample, furthering its aim to be a dominant player in the detection market over the next five years, Bloomberg reported.

Data spanning six cancer types included lung and ovarian, and demonstrated an overall sensitivity of 86% and specificity of 95%, the news report said. While the test could detect early stage cancers, the samples were biased toward later and more developed diseases, it added.

While the findings are "still very early" and Exact Sciences has a long path to bringing the test to market, Cowen analyst Doug Schenkel was said to have been excited by the development, according to the report.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

My goodness!

It appears that "Graill" potential acquisition might be driving EXAS 20+% run today.

OAG Tom

Well dam

New Study Supports Lowering Age of First Colonoscopy
Jan. 31, 2020, at 12:00 p.m.
More
U.S. News & World Report

New Study Supports Lowering Age of First Colonoscopy
More

By Amy Norton
HealthDay Reporter

(HealthDay)

FRIDAY, Jan. 31, 2020 (HealthDay News) -- The rate of colon cancer among Americans spikes sharply between the ages of 49 and 50, a new study finds -- supporting the case for earlier screening for the disease.

Researchers say the uptick between those two ages does not reflect an actual increase in the occurrence of colon cancer but the fact that screening for the disease has traditionally begun at age 50. So "latent" cancers that had been present for some time are caught at that age.

Experts said the findings could have implications for colon cancer screening recommendations, which at the moment are conflicting.

For years, guidelines from various groups said that people at average risk of colon cancer should begin screening at age 50. Earlier screening was reserved for people at increased risk.

But in 2018, the American Cancer Society lowered its recommended threshold to age 45, largely due to a rising incidence of colon cancer among younger Americans.

But the U.S. Preventive Services Task Force -- which sets federal screening standards -- still recommends a starting age of 50 for people at average risk.

Given the debate, Dr. Jordan Karlitz said his team wanted to take a closer look at how Americans' colon cancer rates change by yearly increments in age. Past studies, he explained, have looked at age blocks, like 45 to 49 and 50 to 54.

A year-by-year look, Karlitz said, could give a clearer picture of what's going on among people in their 40s. It has long been suspected that incidence of colon cancer in that age range is higher than statistics show, because most people in their 40s are not screened.

The researchers expected to see an increase in colon cancer between age 49 and 50. What they found was a 46% rise.

"It was a steep uptick," said Karlitz, an associate clinical professor at Tulane University School of Medicine in New Orleans. "We expected we'd see something, but not to that extent."

The pattern probably reflects cancers that started before age 50 -- even years before -- but weren't caught until screening started, according to Dr. Umut Sarpel.

Sarpel, who was not involved in the study, is an associate professor of surgical oncology at Mount Sinai's Icahn School of Medicine in New York City.

"The results of this study support efforts to lower the screening age to less than 50 years," Sarpel said.

The findings, published online Jan. 31 in JAMA Network Open, are based on government cancer data for 2000 through 2015. Karlitz's team focused on colon and rectal cancer rates among 30- to 60-year-olds.

During that period, the rate among 49-year-old Americans was just under 35 cases per 100,000 people. That jumped to 51 cases per 100,000 among 50-year-olds, the investigators found.

The vast majority of cases caught at age 50 -- nearly 93% -- were invasive, which means they would probably require more extensive treatment and had likely been there for some time.

Statistics show that most colon cancers are diagnosed after age 50. However, the rate among younger Americans has been on the rise, for reasons that remain unclear.

An American Cancer Society study found that since the mid-1990s, colon cancer rates among Americans aged 20 to 54 have been steadily inching up -- by between 0.5% and 2% each year. Rectal cancer has risen faster, by 2% to 3% per year.

"It has been known for approximately 15 years that rates of colon and rectal cancers are rising among young patients," said Dr. Joshua Meyer, a radiation oncologist at Fox Chase Cancer Center in Philadelphia. "This appears to be true both under age 40 and between age 40 and 50."

What has been unclear, Meyer said, is how long colon tumors may be growing when they are finally caught through screening.

"This study makes it clear that these have been growing for a number of years," said Meyer, who was not involved in the research.

The increase between ages 49 and 50 was seen not only for cancers confined to the colon and rectum, but also for regional cancers -- meaning the disease has spread into nearby lymph nodes. There was also a small increase (just under 16%) in the most-advanced cancers -- those that have spread to distant sites in the body.

Meyer said it's concerning to see a rise in more-advanced cancers. The findings support "consideration of lowering of the screening age for colorectal cancer," he said.

Researcher Karlitz said he hopes the results "shed light" on the fact that colon cancer is more common among people in their 40s than the statistics suggest.

For now, he said that people should discuss the best screening strategy, including starting age, with their doctor. And everyone -- no matter how young they are -- should act on potential cancer symptoms, Karlitz stressed.

Some potential red flags include a persistent change in bowel habits; abdominal pain or cramping; stool that is dark or has visible blood; and unintended weight loss.

https://www.usnews.com/news/health-news/articles/2020-01-31/new-study-supports-lowering-age-of-first-colonoscopy

mentioned study on CNBC today in the news segment

$EXAS up 10% today back to 94.96

private competition Freenome


*Exact Sciences shares are trading higher. UBS analysts noted that companies with liquid biopsy tests for colon cancer screening will present at this week's 2020 Gastrointestinal Cancers Symposium, but they still 'lag well behind' Exact's Cologuard.

bend over, day

Exact Sciences (EXAS) Stock Has 40% Upside From Here, Says Analyst
Maya Sasson January 14, 2020

Exact Sciences’ (EXAS) preliminary quarterly results blew expectations out of the water.

Yesterday, the molecular diagnostics company released preliminary results for its fourth quarter that exceeded analysts’ estimates. Total revenue for the quarter is expected to land between $294 million and $296 million, reflecting a top-line beat of about $4 million to $6 million.

The better-than-expected outcome was primarily driven by its acquisition of Genomic Health, which was finalized back in November and gave it access to Oncotype DX gene expression tests that have been used in treatment decisions for over 1 million cancer patients globally. During the quarter, Oncotype DX test volume growth of 14%, or total test volume of 41,000, helped Genomic Health generate revenue of between $118 and $119 million, up 13% year-over-year.

On top of this, Cologuard, its FDA approved noninvasive, at-home colon cancer screening test, will most likely see revenue come in within the range of $229 million to $230 million. While this falls in line with the consensus estimate, BTIG analyst Amanda Murphy reminds investors that the difference between consensus and guidance is the highest it has been this year. She points out that “consensus for Cologuard revenue was at the high-end of management’s guidance range for the quarter.” If achieved, the figure would also represent a year-over-year increase of 61%.

Based on the expected Cologuard revenue, it isn’t surprising to the analyst, then, that volumes for the screening test are also expected to match the estimate. The results indicate Cologuard test volume of 477,000 could be in store. This, however, would not only come in above management’s guidance of between 465,000 to 475,000, but also reflect impressive growth of 63%.

While management isn’t offering any 2020 guidance before its earnings call in February, Murphy notes that the results reaffirm her already established bullish thesis. “Since Cologuard was approved in 2014, Exact has secured broad reimbursement coverage, developed a large and experienced sales force, increased its lab capacity to seven million tests per year, and made significant investments in IT infrastructure. We believe Cologuard is currently at an inflection point and expect the company to hit its long-term goal of 40% market penetration by the end of 2030,” she explained. The four-star analyst added, “While not explicitly included in our current valuation model, we are also optimistic around the potential for Exact’s liquid biopsy test for liver cancer.”

Bearing this in mind, Murphy maintained both a Buy rating as well as a $127 price target. This conveys her confidence in Exact’s ability to climb 40% higher in the next twelve months. (To watch Murphy’s track record, click here)

As for the rest of the Street? It turns out that other analysts wholeheartedly agree with the BTIG analyst. Out of 9 total analysts that have published a recommendation over the last three months, 100% see the stock as a Buy. This makes the consensus rating a unanimous Strong Buy. Not to mention the $123.56 average price target puts the upside potential just below Murphy’s forecast at 37%.

https://blog.tipranks.com/exact-sciences-exas-stock-has-40-upside-from-here-says-analyst/

Preliminary Q4 results on Sunday night 7PM



between $294 million and $296 million vs $253.11

https://madison.com/wsj/business/full-speed-ahead-at-exact-sciences-building-hiring-developing-new/article_0356340b-5d8d-5e23-bc62-bc90513b62e0.html?linkId=100000006764726#tracking-source=home-top-story-2

Hey everyone..meet GEN destined to become the new EXAS.

https://stockhouse.com/companies/quote?symbol=t.gen

You ain’t seen nothin yet....

EXAS

Good strong day. Resilient.

that didn't take long :)

big beat for 4th qtr should see ATH's soon

stop posting OTC garbage on the EXAS board

GTHP tests for cervical cancer.
EXAS tests for colon cancer

End of subject.

Sorry but the price Disagrees with you.

Gthp only . 0017
Ha ha ha

No doubt. GTHP Cancer text will definitely replace Exat science

How much must the doctor invest ?

I have used their test, it is easy and fine.
100 % covered by Medicare.

International Stock with 4B Customers guaranteed.
Better Play than EXAS: EXACT Sciences stock.74Per share from nothing 9 years ago. Both EXAS and GTHP focus on Cancer diagnostic.
GHTP is faster more accurate, ( Instant!, Shameless!, painless)
No specimen to ship out for testing,
No lost specimen,
No mixed up specimen,
No expired specimen related to transportation,
Genuine. Single-Use Disposables anti-counterfeiting device
If EXAS is 74 USD, GTHP should be double based on above facts.

Share where just increased to Apx 400M. No need for R/S

Insider % Owned = 87.00%

PE=0

EPS = -0.99